EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes

Anna Vázquez-Oliver, Silvia Pérez-García, Rafael Romero-Pérez, Nieves Pizarro, Diana Galarraga-Shinin, Laura Molina-Porcel, Rafael de la Torre, Rafael Maldonado, Andrés Ozaita iD

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70874 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Anna Vázquez-Oliver und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain. Hauptthemen laut MEDLINE: Down Syndrome, Receptor, Cannabinoid, CB1, Hippocampus, Rimonabant. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Fondation Jérôme Lejeune, Bright Focus foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Down syndrome (DS) is the most common genetic cause of intellectual disability, affecting cognitive function and increasing the risk of early‐onset Alzheimer's disease (AD). The endocannabinoid system may serve as a therapeutic target for cognitive deficits by inhibiting cannabinoid type‐1 receptor (CB1R) function. METHODS CB1R expression was analyzed in the hippocampi of aged DS‐associated AD (DSAD) individuals and middle‐aged Ts65Dn mice. Long‐term oral treatment with the CB1R antagonist rimonabant was used to assess its effects on memory and neuroinflammation in the Ts65Dn mouse model of DS. RESULTS CB1R expression was significantly increased in both aged DSAD subjects (specifically in the dentate gyrus and CA2 posterior hippocampal subregions) and Ts65Dn mice. Long‐term rimonabant treatment improved memory performance, normalized microglial morphology, and reduced plasma inflammatory markers in trisomic mice without preventing neuron decline. DISCUSSION These findings suggest that sustained CB1R inhibition may enhance cognitive function by modulating neuroinflammation, highlighting its therapeutic potential for cognitive impairments in DS. Highlights Cannabinoid type‐1 receptor (CB1R) expression is increased in the posterior hippocampus of aged Down syndrome (DS) subjects and Ts65Dn mice. Long‐term rimonabant treatment enhances memory in middle‐aged Ts65Dn mice. CB1R inhibition shifts neuroinflammatory features in Ts65Dn mice. CB1R inhibition does not halt noradrenergic/cholinergic neurodegeneration in Ts65Dn. CB1R inhibition presents potential for memory improvement in DS‐related deficits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeReceptor, Cannabinoid, CB1HippocampusRimonabantCannabinoid Receptor AntagonistsAnimalsMiceDisease Models, AnimalHumansMaleFemaleAlzheimer DiseaseMice, TransgenicMiddle Aged

Stichwörter der Autor:innen

Down syndromeTs65Dncannabinoid type‐1 receptorendocannabinoid systemmemoryrimonabant

Substanzen

Receptor, Cannabinoid, CB1RimonabantCannabinoid Receptor Antagonists

Autor:innen und Institutionen

  • Laboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
  • Integrative Pharmacology and Systems Neuroscience Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS) and Institute of N…
  • Neurological Tissue Bank, Biobanc-Hospital Clínic-IDIBAPS, Barcelona, Spain.

ORCID-Profile: Andrés Ozaita

Förderung

  • Ministerio de Ciencia, Innovación y Universidades
  • Fondation Jérôme Lejeune
  • Bright Focus foundation
  • Ministerio de Sanidad, Servicios Sociales e Igualdad
  • Departament de Recerca i Universitats, Generalitat de Catalunya
  • Departament d'Economia i Coneixement, Generalitat de Catalunya
  • Institució Catalana de Recerca i Estudis Avançats, ICREA-Acadèmia 2021

Zitieren

APA

Vázquez-Oliver, A., Pérez-García, S., Romero-Pérez, R., Pizarro, N., Galarraga-Shinin, D., Molina-Porcel, L., de la Torre, R., Maldonado, R., & Ozaita, A. (2025). Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70874

Vancouver

Vázquez-Oliver A, Pérez-García S, Romero-Pérez R, Pizarro N, Galarraga-Shinin D, Molina-Porcel L, et al. Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70874

BibTeX
@article{VzquezOliver2025,
  author = {Vázquez-Oliver, Anna and Pérez-García, Silvia and Romero-Pérez, Rafael and Pizarro, Nieves and Galarraga-Shinin, Diana and Molina-Porcel, Laura and de la Torre, Rafael and Maldonado, Rafael and Ozaita, Andrés},
  title = {Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70874}
}
Kostenlos starten →